본문 바로가기
KERD
논문KCI 등재

알츠하이머병에서 APOE e4 유전형과 인지기능, 뇌 부피, 당 대사량 그리고 뇌 아밀로이드 침착과의 연관성

The Association of APOE e4 Genotype With Cognition, Brain Volume, Glucose Metabolism, and Amyloid Deposition in AD

이영민|이현지|김경원|김학진|박경준|이병대|김유준|박제민|문은수|서화규|최경운|윤원배
대한노인정신의학회 (Korean Association For Geriatric Psychiatry)|2023.04|노인정신의학 (Journal of Korean Geriatric Psychiatry)|제27권 제1호|pp. 30-36

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Cognition인지기능Alzheimer disease단어：아포지질단백질 E e4 유전형뇌 부피알츠하이머병.Apolipoprotein E e4Brain volume

초록

Objective: The purpose of this study is to investigate the association of the apolipoprotein E (APOE) e4 genotype with cognition, brain volume, glucose metabolism, and amyloid deposition in patients with Alzheimer disease (AD). Methods: This is cross-sectional study of 69 subjects with AD. All subjects were divided into carriers and non-carriers of the e4 allele. Forty APOE e4 carriers and 29 APOE e4 non-carriers underwent neuropsychological, structural magnetic resonance imaging, [18F]fluorodeoxyglucose positron emission tomography scans (PET) and [18F]florbetaben amyloid PET. Analysis of covariance was conducted to compare the differences on cognition, brain volume, glucose metabolism and amyloid deposition between APOE e4 carriers and non-carriers after controlling demographics. Results: APOE e4 carriers had 50% lower scores of Seoul Verbal Learning Test (delayed recall) compared to non-carriers (0.88±1.65 vs. 1.76±1.75, p<0.05). However, APOE e4 carriers performed better on other cognitive tests than non-carriers (Korean version of Boston Naming Test [11.04±2.55 vs. 9.66±2.82, p<0.05], Rey Complex Figure Test [25.73±8.56 vs. 20.15±10.82, p<0.05], and Stroop test [color response] [48.28±26.33 vs. 31.56±27.03, p<0.05]). APOE e4 carriers had slightly smaller hippocampal volume than non-carriers (3.09±0.38 vs. 3.32±0.38, p<0.05), but greater total brain cortical thickness (1.45±1.55 vs. 1.37±1.24, p<0.05). Amyloid deposition did not differ significantly between APOE e4 carriers and non-carriers, and no significant difference in glucose metabolism was found between groups. Conclusion: We found that APOE e4 genotype is associated with cognition, brain volume in AD, suggesting that APOE e4 genotype could play an important role in the underlying pathogenesis of AD.

Abstract

Objective: The purpose of this study is to investigate the association of the apolipoprotein E (APOE) e4 genotype with cognition, brain volume, glucose metabolism, and amyloid deposition in patients with Alzheimer disease (AD). Methods: This is cross-sectional study of 69 subjects with AD. All subjects were divided into carriers and non-carriers of the e4 allele. Forty APOE e4 carriers and 29 APOE e4 non-carriers underwent neuropsychological, structural magnetic resonance imaging, [18F]fluorodeoxyglucose positron emission tomography scans (PET) and [18F]florbetaben amyloid PET. Analysis of covariance was conducted to compare the differences on cognition, brain volume, glucose metabolism and amyloid deposition between APOE e4 carriers and non-carriers after controlling demographics. Results: APOE e4 carriers had 50% lower scores of Seoul Verbal Learning Test (delayed recall) compared to non-carriers (0.88±1.65 vs. 1.76±1.75, p<0.05). However, APOE e4 carriers performed better on other cognitive tests than non-carriers (Korean version of Boston Naming Test [11.04±2.55 vs. 9.66±2.82, p<0.05], Rey Complex Figure Test [25.73±8.56 vs. 20.15±10.82, p<0.05], and Stroop test [color response] [48.28±26.33 vs. 31.56±27.03, p<0.05]). APOE e4 carriers had slightly smaller hippocampal volume than non-carriers (3.09±0.38 vs. 3.32±0.38, p<0.05), but greater total brain cortical thickness (1.45±1.55 vs. 1.37±1.24, p<0.05). Amyloid deposition did not differ significantly between APOE e4 carriers and non-carriers, and no significant difference in glucose metabolism was found between groups. Conclusion: We found that APOE e4 genotype is associated with cognition, brain volume in AD, suggesting that APOE e4 genotype could play an important role in the underlying pathogenesis of AD.

참고문헌 (39)

  1. Korean dementia observatory 2021, "Ministry of Health and Welfare", Ministry of Health and Welfare, ~ (2022)
  2. Mahley RW, "Apolipoprotein E : far more than a lipid transport protein", Annu Rev Genomics Hum Genet, 1, pp.507~537 (2000)
  3. Han X, "The role of apolipoprotein E in lipid metabolism in the central nervous system", Cell Mol Life Sci, 61, pp.1896~1906 (2004)
  4. Holtzman DM, "Apolipoprotein E and apolipoprotein E receptors : normal biology and roles in Alzheimer disease", Cold Spring Harb Perspect Med, 2, pp.a006312~ (2012)
  5. Strittmatter WJ, "Apolipoprotein E : high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease", Proc Natl Acad Sci U S A, 90, pp.1977~1981 (1993)
  6. Corder EH, "Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families", Science, 261, pp.921~923 (1993)
  7. Saunders AM, "Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease", Neurology, 43, pp.1467~1472 (1993)
  8. Yamazaki Y, "Apolipoprotein E as a therapeutic target in Alzheimer’s disease : a review of basic research and clinical evidence", CNS Drugs, 30, pp.773~789 (2016)
  9. Yamazaki Y, "Apolipoprotein E and Alzheimer disease : pathobiology and targeting strategies", Nat Rev Neurol, 15, pp.501~518 (2019)
  10. Blautzik J, "Relationship between body mass i ndex, ApoE4 status, and PET-based amyloid and neurodegeneration markers in amyloid-positive subjects with normal cognition or mild cognitive impairment", J Alzheimers Dis, 65, pp.781~791 (2018)
  11. Gonneaud J, "Relative effect of APOE ε4 on neuroimaging biomarker changes across the lifespan", Neurology, 87, pp.1696~1703 (2016)
  12. Cosentino S, "APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease", Neurology, 70(19 Pt 2), pp.1842~1849 (2008)
  13. Martins CA, "APOE alleles predict the rate of cognitive decline in Alzheimer disease : a nonlinear model", Neurology, 65, pp.1888~1893 (2005)
  14. Craft S, "Accelerated decline in apolipoprotein E-epsilon4homozygotes with Alzheimer’s disease", Neurology, 51, pp.149~153 (1998)
  15. Hirono N, "Accelerated memory decline in Alzheimer’s disease with apolipoprotein epsilon4allele", J Neuropsychiatry Clin Neurosci, 15, pp.354~358 (2003)
  16. Kanai M, "Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer’s disease", Neurosci Lett, 267, pp.65~68 (1999)
  17. Chang YL, "APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer’s disease", Alzheimers Dement, 10, pp.336~348 (2014)
  18. Kleiman T, "Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer’s disease : retrospective and prospective analysis", Dement Geriatr Cogn Disord, 22, pp.73~82 (2006)
  19. Growdon JH, "Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer’s disease", Neurology, 47, pp.444~448 (1996)
  20. Holmes C, "Apolipoprotein E : non-cognitive symptoms and cognitive decline in late onset Alzheimer’s disease", J Neurol Neurosurg Psychiatry, 61, pp.580~583 (1996)
  21. Samuraki M, "Glucose metabolism and gray-matter concentration in apolipoprotein E ε4 positive normal subjects", Neurobiol Aging, 33, pp.2321~2323 (2012)
  22. Jack CR Jr, "Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease", Ann Neurol, 43, pp.303~310 (1998)
  23. Juottonen K, "Major decrease in the volume of the entorhinal cortex in patients with Alzheimer’s disease carrying the apolipoprotein E epsilon4allele", J Neurol Neurosurg Psychiatry, 65, pp.322~327 (1998)
  24. Filippini N, "Anatomically-distinct genetic associations of APOE epsilon4allele load with regional cortical atrophy in Alzheimer’s disease", Neuroimage, 44, pp.724~728 (2009)
  25. Geroldi C, "APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD", Neurology, 53, pp.1825~1832 (1999)
  26. Kang Y, "Seoul neuropsychological screening battery" (2012), Human Brain Research &Consulting Co
  27. Lehtovirta M, "Clinical and neuropsychological characteristics in familial and sporadic Alzheimer’s disease : relation to apolipoprotein E polymorphism", Neurology, 46, pp.413~419 (1996)
  28. Wolk DA, "Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease", Proc Natl Acad Sci U S A, 107, pp.10256~10261 (2010)
  29. Mattsson N, "Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study", Alzheimers Res Ther, 10, pp.77~ (2018)
  30. Hashimoto M, "Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer’s disease", Neurology, 57, pp.1461~1466 (2001)
  31. Lehtovirta M, "SPECT and MRI analysis in Alzheimer’s disease : relation to apolipoprotein E epsilon 4 allele", J Neurol Neurosurg Psychiatry, 60, pp.644~649 (1996)
  32. Lehtovirta M, "Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes", Neuroscience, 67, pp.65~72 (1995)
  33. Tiraboschi P, "Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease", Neurology, 62, pp.1977~1983 (2004)
  34. Drzezga A, "Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease", Neurology, 72, pp.1487~1494 (2009)
  35. Berg L, "Clinicopathologic studies in cognitively healthy aging and Alzheimer’s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype", Arch Neurol, 55, pp.326~335 (1998)
  36. Yi D, "Beta-amyloid associated differential effects of APOE ε4 on brain metabolism in cognitively normal elderly", Am J Geriatr Psychiatry, 22, pp.961~970 (2014)
  37. Small GW, "Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease", JAMA, 273, pp.942~947 (1995)
  38. Emrani S, "APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease : a systematic review", Alzheimers Res Ther, 12, pp.141~ (2020)
  39. Li W, "Effect of APOE ε4genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment", Eur J Neurol, 30, pp.587~596 (2023)

관련 논문AI추천

아밀로이드 양성인 인지기능저하군에서 APOE ε4 유전형이 내측두엽 위축에 미치는 영향: 자기공명영상 장기연구김경원, 김지혜, 김학진, 문은수, 박경준, 서화규, 이병대, 이영민, 이현지, 최경운대한노인정신의학회 · 노인정신의학2024 · 제28권 제1호알츠하이머병 치매에서 대뇌 아밀로이드 축적 여부에 따른 임상적 특성의 차이고강, 고현웅, 김유경, 김현정, 백혜원, 변민수, 이다현, 이동영, 이동우, 이승훈, 이영화, 이윤상, 이준영, 이준호, 전소연, 최영민, 추경진, 한나영대한노인정신의학회 · 노인정신의학2016 · 제20권 제2호A Comparison of Apolipoprotein E Polymorphism in Alzheimer’s Disease and Subcortical Vascular Dementia in Koreans권오대, Jun Woo Kim대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2015 · 제14권 제2호Incidence and Cognitive Decline of Alzheimer’s Disease and Other Dementia by Apolipoprotein ε4 Allele Presence: A Community-Based Cohort Study in Korean ElderlyAlexander Han, Jun-Young Lee, Soowon Park, So Young Yoo대한신경정신의학회 · PSYCHIATRY INVESTIGATION2022 · 제19권 제3호기억장애성 경도인지장애 환자의 양전자방출단층촬영검사에서 아밀로이드 침착이 해마 대사량에 미치는 영향 : 예비연구김기옥, 김수연, 김지훈, 김학진, 문은수, 문치웅, 박경준, 박제민, 서화규, 이강윤, 이병대, 이영민, 정영인, 정희정대한생물치료정신의학회 · 생물치료정신의학2019 · 제25권 제3호조기발병 경도인지장애에서 해마 부분체의 구조적 변화문석우, 유도연대한생물치료정신의학회 · 생물치료정신의학2021 · 제27권 제1호

이 간행물의 다른 논문 (5건)

일지역 치매고위험군의 인지기능에 영향을 주는 요인: 독거노인 중심으로이윤희, 김다은, 김정란, 전소연pp. 1-7노인의 우울 증상이 일반 및 암 건강검진 수검에 미치는 영향김석현, 조승원pp. 8-15외상 후 스트레스 장애 잔단 유무에 따른 고령의 재향 군인의 뇌백질 고신호 차이배희원, 이은영, 이승훈, 최하연, 최진희pp. 16-22노년기 우울 증상 평가에서 주관적 척도와 객관적 척도 간 상관성 연구박채린, 추일한pp. 23-29치매, 정신증, 기분장애 환자군에서 관찰되는 MMSE 세부 항목별 점수 비교정수봉, 진아영, 안호영, 백인호, 김낙영pp. 37-42
원문 보기